Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients

Abstract Introduction Disease‐modifying treatments for Alzheimer's disease (AD) are likely to be offered only to patients with molecular evidence for Alzheimer pathology and expanded to patients with prodromal AD. We calculated the potential future costs of expanding the number of positron emis...

Full description

Saved in:
Bibliographic Details
Main Authors: Raphael Wittenberg, Martin Knapp, Maria Karagiannidou, John Dickson, Jonathan M. Schott
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Online Access:https://doi.org/10.1016/j.trci.2019.06.001
Tags: Add Tag
No Tags, Be the first to tag this record!